The function loss of the TSC2 gene leads to aberrant mTOR pathway activation and multiple tumors including subependymal giant cell astrocytomas, angiomyolipomas, lymphangioleiomyomatosis, and angiofibromas (Henske et al., 2016). This evidence concerns the gene TSC2 and angiomyolipoma.